Why start treatment with TIGLUTIK now?
TIGLUTIK is an oral suspension (mildly thick liquid) formulation of riluzole. It was developed specifically to meet the needs of people with ALS. Since TIGLUTIK is approved for use throughout all stages of ALS, patients can start taking it as soon as they are diagnosed with ALS. TIGLUTIK is the only formulation of riluzole approved for both oral and PEG tube administration.
One dose of TIGLUTIK 50 mg (10 mL) is equivalent to one RILUTEK® (riluzole) 50 mg tablet and it is taken twice a day, every 12 hours.
Click here for information to Ask Your Doctor if TIGLUTIK is Right for You.